Evaluation of the Biological Response to Clopidogrel in Patients With Ischemic Stroke "AAPIX"


Phase N/A Results N/A

Summary of Purpose

Ischemic stroke (AIC) is the leading cause of non-traumatic disability in adults, the second leading cause of dementia and the third leading cause of death in France. Clopidogrel is one of the recommended first line in the secondary prevention of AIC non cardioembolic origin. However recurrences occur in approximately 9% of patients receiving clopidogrel. Some studies in patients with coronary artery disease...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 30 December 2015.

1 Sep 2013 27 Sep 2013 1 Dec 2015 1 Dec 2015 1 Dec 2015 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Observation: Case-Only
  • Perspective: Prospective
  • Sampling: Non-Probability Sample